Crossject reports financial results and business highlights for the first six months of 2024
Available cash €5.95 million, up from €2.3 million on December 31, 2023 Reports stable investments in R&D and consolidation of operating income from BARDA Company on track to successfully file for the Emergency Use Authorization for its epilepsy rescue …